Dofequidar fumarate (Synonyms: MS-209) |
| Catalog No.GC13375 |
MDR reversal agent
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 153653-30-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Dofequidar fumarate is a multidrug-resistant (MDR) - reversal agent [1].
Dofequidar fumarate is a quinoline derivative and has highly potent reversing effect on multidrug-resistant tumor cells. It prevents the transport of antitumor drugs through interacting with the drug-efflux pump P-glycoprotein directly and thereby reverses MDR. In vincristine (VCR)-resistant P388/VCR cells and Adriamycin (ADM)- resistant P388/ADM cells, dofequidar fumarate at 1μM and 3μM can completely reverse the drug resistance. It also shows significant effects on the MDR K562 cells. Furthermore, in mice model bearing HCT-15 xenografts, combination therapy of dofequidar fumarate and docetaxel induces remarkable tumor growth inhibition. Dofequidar fumarate also shows significant reversing effect in MCF-7/ADM-bearing mice [1, 2].
References:
[1] Sato W, Fukazawa N, Nakanishi O, et al. Reversal of multidrug resistance by a novel quinoline derivative, MS-209. Cancer chemotherapy and pharmacology, 1995, 35(4): 271-277.
[2] Naito M, Matsuba Y, Sato S, et al. MS-209, a quinoline-type reversal agent, potentiates antitumor efficacy of docetaxel in multidrug-resistant solid tumor xenograft models. Clinical cancer research, 2002, 8(2): 582-588.
Average Rating: 5 (Based on Reviews and 5 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *